Market Overview

The global polynucleotides injectable market was valued at USD 131.05 Million in 2024 and is projected to reach USD 490.68 Million by 2033, exhibiting a CAGR of 14.40% between 2025 and 2033. The market growth is primarily driven by the rising demand for advanced wound healing solutions, the increasing popularity of aesthetic treatments such as skin rejuvenation, and adoption in chronic wound management. Asia Pacific currently dominates the market with over 46.5% share as of 2024. 

Study Assumption Years

  • Base Year: 2024
  • Historical Year/Period: 2019-2024
  • Forecast Year/Period: 2025-2033

Polynucleotides Injectable Market Key Takeaways

  • The global polynucleotides injectable market size was valued at USD 131.05 Million in 2024.
  • The market is expected to grow at a CAGR of 14.40% during the forecast period of 2025-2033.
  • Asia Pacific held the largest market share, accounting for over 46.5% in 2024.
  • The increasing prevalence of diabetic foot ulcers, affecting around 33 million people globally, drives demand for these injectables due to their regenerative properties promoting tissue repair.
  • The U.S. market accounts for 86.20% of the North American polynucleotides injectable market share, reflecting high adoption for wound care and aesthetic treatments.
  • MedSpas lead usage by end-use segment with a 43.2% market share in 2024, driven by demand for non-invasive aesthetic treatments.
  • Eyes segment dominates by application with 62.5% market share in 2024, due to demand for treatments targeting signs of aging around the eyes.

Sample Request Link: https://www.imarcgroup.com/polynucleotides-injectable-market/requestsample

Market Growth Factors

The polynucleotides injectable drugs market is driven by an increase in DFU cases with estimates indicating 33 million patients worldwide, their regenerative properties as they trigger tissue regeneration and exert an anti-inflammatory effect on DFUs and other chronic wounds such as burns and surgical wounds. Polynucleotides injectable drugs stimulate biological processes such as cellular proliferation and collagen deposition and are currently the preferred therapy in health care systems that favor advanced treatment for wound healing.

The increasing usage of aesthetic procedures is expected to propel market growth. Polynucleotides are used in anti-aging and skin rejuvenation treatments for collagen formation promotion and skin elasticity increase. Aesthetic consumers increasingly recognize the utility in these non-intrusive procedures to treat skin conditions that correlate with aging, like wrinkles and fine lines. Clinics and dermatologists market these as alternatives to botox and filler injections, especially in more affluent countries with higher disposable incomes and hence greater interest in cosmetic procedures.

Regulatory pathways contribute to growth along with wider acceptance. Greater than 140 polynucleotide injectables gained approval for use in Europe, and streamlined regulatory pathways and continuing clinical data showing injectable safety and efficacy support injectable uptake in wound care and aesthetic indications worldwide. The existence of this validation allows manufacturers and providers to introduce these products to new markets with confidence.

Market Segmentation

Analysis by Application:

  • Eyes: Constituting around 62.5% of the market in 2024, this segment leads due to high demand for treatments addressing aging signs like fine lines, wrinkles, and puffiness around the delicate skin of the eyes. Polynucleotide injectables promote collagen growth and skin elasticity, offering a non-invasive approach for eye area rejuvenation.
  • Lips
  • Forehead
  • Jawline and Cheekbones
  • Others

Analysis by End Use:

  • MedSpas: Leading with approximately 43.2% market share in 2024, MedSpas benefit from growing demand for non-invasive aesthetic treatments, offering effective and quick skin rejuvenation procedures that attract consumers aiming to reduce aging signs without surgery.
  • Aesthetic and Cosmetic Centers
  • Hospitals

Regional Insights

Asia Pacific dominates the polynucleotides injectable market with over 46.5% market share in 2024. This leadership is driven by increasing healthcare investments, rising disposable incomes, and a large, diverse population. Key countries such as Japan, China, and South Korea are rapidly adopting advanced medical technologies and aesthetic treatments. The region's aging population and growing chronic conditions like diabetes further increase demand for effective wound care solutions and non-invasive skin rejuvenation procedures, supporting sustained market growth.

Recent Developments & News

In August 2024, Thérapie Clinic, Ireland's leading medical aesthetic group, launched Polynucleotides, an innovative injectable bio-stimulator, across over 70 clinics. This treatment reportedly reduces fine lines and wrinkles by 91% and stimulates fibroblast cells to boost collagen production, enhancing skin firmness and youthfulness. Nurse Nicky, Head of Injectable Growth, dubbed it the "king of skin treatments," highlighting its transformative aesthetic potential.

In February 2024, REJURAN, known as 'salmon sperm injections,' was launched in Australia. This polynucleotide gel derived from wild salmon DNA through proprietary technology promotes skin restoration and repair while reducing inflammation. Previously popular in South Korea since 2015, REJURAN is now available in Australia and New Zealand via exclusive distributor K Bridge Medical, with notable celebrity endorsements.

Key Players

  • Ameela
  • Fox Group International
  • HTL Biotechnology
  • Mastelli Srl
  • PharmaResearch
  • Promoitalia Group Spa

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization: https://www.imarcgroup.com/request?type=report&id=27701&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302